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Background: Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive
individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of
NADC from 2004–2010, and described subsequent mortality and predictors of these.
Methods: Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC,
1st February 2010, death or six months after the patient’s last visit. Incidence rates were estimated for each year of
follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following
NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of
NADC diagnosis until the patient’s death, 1st February 2010 or 6 months after the patient’s last visit. Factors
associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards
regression.
Results: Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY
[95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time
trends for lung cancer, anal cancer and Hodgkin’s lymphoma were broadly consistent. Kaplan-Meier cumulative
mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and
47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer
(compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis
and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC
remained stable over the period 2004–2010 in this large observational cohort.
Conclusions: The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but
has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated
with mortality following a diagnosis of NADC.
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Since the introduction of combination antiretroviral ther-
apy (cART), there has been a dramatic decrease in the
incidence of AIDS-related morbidity and mortality in
HIV-positive patients [1]. However, while the incidence of
AIDS-defining cancers (ADC) has steadily declined, there
have been reports of an apparent increase in the number
of non-AIDS-defining cancers (NADC) [2-11] and in-
creases in cancer-related mortality [12,13]. This has led to
new challenges for those responsible for the management
and treatment of HIV-positive individuals.
There are several factors to consider in assessing
trends in incidence of NADC. As age is an important
risk factor for the development of many NADC, and as
the proportion of HIV-positive patients above the age of
50 has increased, any apparent increase in incidence
may in part simply reflect the normal ageing process in
this population [4,14]. Furthermore, given the lifestyle
characteristics of many individuals living with HIV, the
increase in survival due to cART may also result in in-
creased exposure of the population to oncogens such as
viral co-infections, tobacco, alcohol and sun exposure,
which may all contribute to an increased incidence of
NADC [15,16].
In the pre-/early-cART era, the survival of HIV-positive
patients diagnosed with cancer was significantly poorer
than that of uninfected patients with cancer [17,18]. These
findings may be attributable to more advanced cancer
stage and low performance status at cancer diagnosis and
other HIV-associated opportunistic diseases among HIV-
positive patients [17,19] as well as the impact of an in-
creased burden of traditional risk factors, such as smoking
[14,20], in this population. However, there are only limited
data on the underlying causes of death in patients with a
NADC in the setting of HIV.
We studied a large cohort of HIV-positive individuals
across Europe and Australia to assess the incidence of
NADC over the period 2004–2010 and to describe mor-
tality rates, and predictors of mortality, after a diagnosis
of cancer.
Methods
The D:A:D Study is a prospective, observational study
formed by the collaboration of 11 cohorts that follow
HIV-positive persons from 212 clinics in Europe,
Australia and the United States. The main objective of
the D:A:D Study is to assess the incidence of myocardial
infarction and other cardiovascular disease endpoints in
HIV-positive persons, and to describe associations be-
tween these endpoints and antiretroviral therapy [21].
However, following reports of a possible relationship be-
tween the use of antiretroviral therapy and other long-
term adverse effects, the study protocol was modified in
September 2008 to include the collection of informationon three additional endpoints: NADC, end-stage renal
disease and chronic liver disease. The primary objective
of the analyses of the NADC endpoint is to assess the
possible relationship between exposure to cART and the
risk of NADC, with a secondary objective being to assess
the possible association between immunodeficiency and
NADC. These analyses are ongoing and will be reported
separately. All participating cohorts followed local na-
tional guidelines/regulations regarding patient consent
and/or ethical review. In particular, of the countries rep-
resented by the participating cohorts, only Switzerland
and Australia require specific ethical approval for D:A:D
in addition to that required for their national cohorts
(Swiss HIV Cohort Study and AHOD), both of which
have obtained this approval. France, Italy, and Belgium
do not require specific ethical approval over-and-above
that required for the individual cohorts (Nice/Aquitaine,
Brussels St. Pierre and IcoNA, respectively). Neither the
Netherlands (ATHENA) nor the United States (CPCRA)
require specific ethical approval as data are provided as
part of HIV care in the first instance, and as the datasets
are non-identifiable public use datasets in the second in-
stance. For the EuroSIDA study (which includes the data
from the BASS and Swedish cohorts), which contains
participants from across many European countries, each
participating site has a contractual obligation to ensure
that data collection and sharing is done in accordance
with national legislation; each site principal investigator ei-
ther maintains appropriate documentation from an ethical
committee (if required by law) or has a documented writ-
ten statement to say that this is not required.
End-points
Eight of the 11 D:A:D cohorts have provided ongoing in-
formation on all new NADC (any non-AIDS malignant
disease other than basal or squamous cell skin cancer
and pre-cancers) occurring after the protocol change on
1st February 2008 (the Swiss HIV Cohort, ATHENA, the
Nice HIV Cohort, the ANRS C03 Aquitaine Cohort,
EuroSIDA, the Australian HIV Observational Database,
the ICONA Foundation Study and the Brussels St. Pierre
Cohort). However, as the eight cohorts had been system-
atically collecting information on all new NADC that
occurred from 2004 or earlier, information was also
collected retrospectively on events occurring from 1st
January 2004 until 31st January 2008.
Detailed information on all NADC is collected on a
specific case report form (CRF); information collected in-
cludes date of diagnosis, type/location of cancer and hist-
ology/cytology report or other diagnostic method. Stage of
disease (localised, disseminated or unknown) was available
for some specific types of cancers only (particularly lung/
anal cancers and Hodgkin’s lymphoma). Written guide-
lines for the completion of CRFs were distributed in 2007,
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prior to data collection. Intensive quality assurance, includ-
ing event monitoring, took place in 2009/2010. All reported
events are evaluated and classified, where possible, as
definite, possible or probable cancers by an independent
committee that includes an oncologist. Classification
reflects the degree of certainty in the NADC diagnosis:
Definite: based on supportive histology/cytology
reports or a detailed summary of histopathological
findings;
Possible: based on a precise clinical description of the
case, and where treatment had been initiated to
support the description of an invasive NADC, but
lacking supportive histopathological findings;
Probable: based on clinical suspicion, biochemical or
ultrasound findings.
The present analysis is based on data collected up to
1st February 2010. By that date, reports had been re-
ceived on 1993 potential NADC; after excluding NADC
events occurring prior to baseline (the latest of 1 January
2004 or entry in the D:A:D Study) and apparent NADC
events that were subsequently rejected as they did not
meet the study criteria for a definite, possible or prob-
ably NADC (AIDS-defining cancers, dysplasias, subse-
quent events following a first event, in situ cancers
particularly for the anal and head/neck regions), 880
NADC were ultimately included in analyses. The major-
ity of rejected events occurred prior to baseline. Of the
880 included events, 472 were accompanied by a com-
pleted CRF and could be classified as either definite (n =
383, 81.3%), probable (n = 38, 8.1%) or possible (n = 44,
9.3%); 1 event was a known relapse and 6 were unclassi-
fiable even with the completed CRF. The remaining 408
events without a CRF were recorded as unclassifiable.
Information on cause of death was captured using The
Coding Causes of Death in HIV (CoDe) form [22].
Statistical methods
Follow-up for the analyses of NADC incidence started
on the latest of 1st January 2004 or the date of enrol-
ment in the D:A:D Study, and finished at the earliest of
the date of diagnosis of a new NADC, 1st February 2010
(the cut-off date for the present dataset), death or six
months after the patient’s last clinic visit. Crude inci-
dence rates were estimated for each year of follow-up
from 2004, overall and stratified by gender, age attained
and mode of HIV acquisition. Incidence rates were also
estimated separately for the three most frequently occur-
ring cancers (Hodgkin’s lymphoma, anal and lung can-
cers). Age-adjusted incidence rates (adjusted to the agedistribution of the cohort in 2004) were also estimated
for all NADC combined. As it was not possible to esti-
mate age-adjusted rates for specific cancers due to the
small number of these events, the impact of the ageing
population on calendar trends for specific cancers was
investigated via Poisson regression with adjustment for
age (as a time-updated covariate).
Cumulative risk of all-cause mortality following NADC
diagnosis was summarised using Kaplan-Meier methods.
Follow-up for these analyses started on the date of NADC
diagnosis and finished at the earliest of the patient’s death,
1st February 2010 or 6 months after the patient’s last clinic
visit. Factors associated with mortality following NADC
diagnosis were identified using Cox proportional hazards
regression, with the following factors at NADC diagnosis
considered for inclusion: gender, mode of HIV acquisition,
ethnic group (categorised as white/non-white), smoking
status (current smoker, ex-smoker, never smoker, un-
known), hepatitis C virus (HCV) coinfection status (posi-
tive: seropositive and HCV RNA positive or HCV RNA
unknown; negative: seronegative, or seropositive but HCV
RNA negative; or not tested) and hepatitis B virus (HBV)
coinfection status (positive: active infection [HB surface
antigen, HBe antigen, or HBV DNA positive]; positive: in-
active infection [HB surface antigen negative, anti-HBe
antibody positive, or HBV DNA negative]; negative or vac-
cinated; or not tested), age at diagnosis, year of diagnosis,
the nadir and latest CD4 count and latest HIV RNA level
at diagnosis, whether the patient had a prior ADC/NADC
and the type of NADC. Note that cART status at NADC
diagnosis was not included in these analyses as the major-
ity of patients were receiving cART. Analyses of survival
after a diagnosis of the specific cancers additionally con-
sidered stage of disease (disseminated, localised or un-
known), specific type of cancer (for lung: adenocarcinoma,
small cell or unknown; for Hodgkin’s lymphoma: nodular
sclerosis, other or unknown) and, for Hodgkin’s lymph-
oma only, the haemoglobin level at diagnosis. Those fac-
tors that were associated with mortality in univariate
analyses (p < 0.2) were considered for inclusion in a multi-
variable model. A backwards stepwise approach was then
used to identify the factors independently associated with
mortality following cancer diagnosis (p-value for retention
in model = 0.1). The assumption of proportional hazards
was tested through the inclusion of interaction terms be-
tween each covariate and the log of time in the main
model. As sensitivity analyses, we also repeated our ana-
lyses to identify predictors of mortality from cancer only.
All analyses were performed using SAS version 9.3.
Results
The eligible population (8 of the 11 D:A:D cohorts) in-
cludes 41,746 HIV-positive individuals (Table 1). At
baseline, the average age of participants was 39 years
Table 1 Baseline characteristics of study participants, overall and stratified according to whether they developed a
NADC during prospective follow-up
All patients Developed a NADC
Yes No
Total number 41746 (100.0) 880 (100.0) 40866 (100.0)
Gender*, n (%) Male 30572 (73.2) 708 (80.5) 29864 (73.1)
Female 11143 (26.7) 172 (19.6) 10971 (26.9)
Age (years) Median (IQR) 39 (33, 46) 47 (41, 56) 39 (33, 46)
Mode of HIV acquisition, n (%) Men having sex with men 18251 (43.7) 408 (46.4) 17843 (43.7)
Injection drug user 6075 (14.6) 153 (17.4) 5922 (14.5)
Heterosexual 14621 (35.0) 256 (29.1) 14365 (35.2)
Other/unknown 2799 (6.7) 63 (7.2) 2736 (6.7)
Ethnic group, n (%) White 20870 (50.0) 479 (54.4) 20391 (49.9)
Black 2866 (6.9) 27 (3.1) 2839 (7.0)
Other 838 (2.0) 11 (1.3) 827 (2.0)
Unknown/not collected 17172 (41.1) 363 (41.3) 16809 (41.1)
BMI (kg/m2), n (%) <18 1241 (3.0) 39 (4.4) 1202 (2.9)
≥18, ≤26 24674 (59.1) 521 (59.2) 24153 (59.1)
>26, ≤30 4751 (11.4) 99 (11.3) 4652 (11.4)
>30 1643 (3.9) 43 (4.9) 1600 (3.9)
Unknown 9437 (22.6) 178 (20.2) 9259 (22.7)
CD4 count (cells/mm3) Median (IQR) 434 (282, 620) 393 (235, 583) 435 (284, 621)
Nadir CD4 count (cells/m3) Median (IQR) 223 (97, 377) 144 (50, 290) 225 (99, 379)
HIV RNA (log10 copies/ml) Median (IQR) 2.3 (1.7, 4.3) 1.7 (1.7, 3.9) 2.3 (1.7, 4.3)
Prior NADC, n (%) 585 (1.4) 48 (5.5) 537 (1.3)
Prior ADC, n (%) 2436 (5.8) 91 (10.3) 2345 (5.7)
Smoking status, n (%) Current Smoker 15526 (37.2) 381 (43.3) 15145 (37.1)
Ex-smoker 8121 (19.5) 226 (25.7) 7895 (19.3)
Never smoked 10227 (24.5) 151 (17.2) 10076 (24.7)
Unknown 7872 (18.9) 122 (13.9) 7750 (19.0)
HCV positive, n (%) 4431 (10.6) 105 (11.9) 4326 (10.6)
HBV positive, n (%) 1751 (4.2) 56 (6.4) 1695 (4.2)
Any use of ARV, n (%) 27778 (66.5) 718 (81.6) 27060 (66.2)
*Information on gender is missing for 31 participants.
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The median (IQR) CD4 count and HIV RNA at baseline
were 434 (282–620) cells/mm3 and 2.3 (1.7-4.3) log10
copies/ml. Only 1.4% and 5.8% of participants, respect-
ively, had a prior NADC or ADC.
The study participants were followed for 176,775
person-years (PY) (median [IQR] 5.0 [2.4-6.1]); the pro-
portion of participants in whom follow-up was censored
more than a year prior to death or the administrative cen-
soring date for the cohort (assumed lost-to-follow-up)
ranged from 1.9%-4.5% in each year. Over the study
period, 880 (2.1%) participants developed a new NADC
(incidence: 4.98/1000 PY, 95% confidence interval [CI]
[4.65-5.31]). The three most frequent NADC were lungcancer (n = 140, 0.79 [0.66-0.92]/1000 PY), Hodgkin’s
lymphoma (n = 112, 0.63 [0.52-0.75]/1000PY), and anal
cancer (n = 79, 0.45 [0.35-0.55]/1000PY) (Table 2). Also
shown in Table 2 is the number of participants that devel-
oped an ADC (n = 621) and type of ADC over follow-up.
Characteristics of participants at NADC diagnosis, strati-
fied by the type of NADC, are shown in Table 3. There
were some notable differences: participants with Hodgkin’s
lymphoma tended to be younger at diagnosis than those
with other cancer types; those with anal cancer had lower
median nadir CD4 cell count at NADC diagnosis; a higher
percentage of participants with anal cancer had previously
had an ADC. Information on stage of disease was available
for 163 participants with lung/anal cancer and Hodgkin’s
Table 2 Summary of NADC and ADC reported in the
D:A:D study from 2004-2010
n (% of total events)
Number of NADC events 880 (100.0)
Lung cancer 140 (15.9)
Hodgkin’s lymphoma 112 (12.7)
Anal cancer 79 (9.0)
Head and neck cancers 71 (8.1)
Liver cancer 59 (6.7)
Prostate 57 (6.5)
Breast cancer 43 (4.9)
Malignant melanoma 31 (3.5)
Colon cancer 26 (3.0)
Bladder cancer 21 (2.4)
Rectal 20 (2.3)
Gynecological cancers* 14 (1.6)
Stomach 13 (1.5)
Penile cancer 12 (1.4)
Kidney cancers 12 (1.4)
Acute myeloid leukemia 11 (1.3)
Metastasis of adenocarcinoma 9 (1.0)
Testicular 9 (1.0)
Lip cancer 6 (0.7)
Uterus 5 (0.6)
Brain cancer 5 (0.6)
Multiple myeloma 5 (0.6)
Metastasis of other cancer type 5 (0.6)
Metastasis of squamous cell carcinoma 5 (0.6)
Metastasis unspecified 4 (0.5)
Chronic lymphatic leukemia 2 (0.2)
Chronic myeloid leukemia 2 (0.2)
Connective tissue cancer 2 (0.2)
Bone cancer 1 (0.1)
Acute lymphatic leukemia 1 (0.1)
Leukemia unspecified 1 (0.1)
Type unknown 8 (0.9)
Unknown primary cancer 7 (0.8)
Other** 82 (9.3)
Number of ADC events 621 (100.0)
Kaposi’s sarcoma 331 (53.3)
Non-Hodgkin’s lymphoma 251 (40.4)
Cervical carcinoma 46 (7.4)
*Other than uterus and cervical cancer.
**Esophageal cancer, pancreas cancer, gall bladder cancer.
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(76.3%) and Hodgkin’s lymphomas (83.3%) were dissemi-
nated, whereas the majority of anal cancers were localized
(60.8%).
Incidence over time
The mean age of participants increased from 41.3 in 2004
to 46.0 years in 2009/10. The incidence of NADC /1000
PY [95% confidence interval] was 4.64 [3.81-5.47], 4.50
[3.70-5.30], 5.43 [4.59-6.26], 6.07 [5.20-6.95], 5.06 [4.26-
5.85] and 4.15 [3.45-4.84] in the years 2004, 2005, 2006,
2007, 2008 and 2009/2010 respectively (Figure 1, p = 0.01,
Poisson regression). Age-adjusted incidence rates for these
6 years were 4.64, 4.30, 5.06, 5.42, 4.54 and 3.50/1000 PY
respectively. Thus, the incidence of a first NADC did not
vary substantially over the study period after age adjust-
ment (p = 0.91, Poisson regression). NADC incidence
rates (/1000 PY) were higher in men than in women
(5.47 [95% CI 5.07-5.88] vs. 3.63 [3.09-4.17]) and in-
creased with age attained (0.69 [0.33-1.27], 1.70 [1.34-
2.06], 4.71 [4.21-5.22], 8.56 [7.50-9.61] and 15.27
[13.16-17.38] in those aged <30, 30–39, 40–49, 50–59
and ≥60 years respectively). Incidence rates were lower
in those infected via heterosexual sex (4.15 [3.64-4.66])
than in men-who-have-sex-with-men (MSM) (5.23
[4.72-5.73]), IDU (5.93 [4.99-6.87]) and those of other
or unknown mode of HIV acquisition (5.61 [4.23-7.00]).
When considering the three most frequently occurring
NADC separately, there continued to be no trend for an
increasing or decreasing incidence over time (Figure 1),
either before or after adjusting for age. Each of the three
most frequently occurring NADC was more common in
men than in women and increased in frequency with age
(data not shown).
All-cause mortality following NADC diagnosis
Of the 880 individuals with a NADC, 327 (37.2%) had
died of any cause by 1st February 2010. Kaplan-Meier
cumulative mortality estimates at 1, 3 and 5 years after
NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0%
[38.2-45.8] and 47.3% [42.4-52.2], respectively, with a
median survival time of 5.5 years (Figure 2). Cumulative
mortality estimates were particularly high in the 140 in-
dividuals diagnosed with lung cancer (57.2% [48.4-65.9]
and 77.0% [67.3-86.8] at 1 and 2.5 years, respectively).
The 79 individuals diagnosed with anal cancer had cu-
mulative mortality estimates of 15.6% [7.5-23.8] and
30.7% [18.2-43.2] at 1 and 3 years, respectively, whereas
the 112 individuals diagnosed with Hodgkin’s lymphoma
had cumulative mortality estimates of 18.4% [11.1-25.8]
and 24.5% [16.0-33.0].
In total, 289 of the 327 (88.4%) participants who died,
died from their NADC, with 4 (1.2%) dying from an
ADC, and 8 (2.5%) dying from a non-malignant cause
Table 3 Selected characteristics of study participants at the time of NADC diagnosis
Lung cancer Hodgkin’s lymphoma Anal cancer Any NADC
Total number 140 (100.0) 112 (100.0) 79 (100.0) 880 (100.0)
Gender, n (%) Male 120 (85.7) 95 (84.8) 69 (87.3) 708 (80.5)
Female 20 (14.3) 17 (15.2) 10 (12.7) 173 (19.5)
Age (years) Median (IQR) 54 (47, 59) 43 (38, 50) 48 (44, 51) 50 (44, 59)
Mode of HIV acquisition, n (%) Men having sex with men 63 (45.0) 61 (54.5) 52 (65.8) 408 (46.4)
Injection drug user 25 (17.9) 15 (13.4) 15 (19.0) 153 (17.4)
Heterosexual 39 (27.9) 29 (25.9) 7 (8.9) 256 (29.1)
Other/unknown 13 (9.3) 7 (6.3) 5 (6.3) 63 (7.2)
Ethnic group, n (%) White 72 (51.4) 70 (62.5) 46 (58.2) 479 (54.4)
Black 1 (0.7) 4 (3.6) 1 (1.3) 27 (3.1)
Other 0 (−) 6 (5.4) 0 (−) 11 (1.3)
Unknown/not collected 67 (47.9) 32 (28.6) 32 (40.5) 363 (41.3)
BMI (kg/m2), n (%) <18 10 (7.1) 3 (2.7) 3 (3.8) 46 (5.2)
≥18, ≤26 64 (45.7) 69 (61.6) 48 (60.8) 439 (49.9)
>26, ≤30 9 (6.4) 17 (15.2) 5 (6.3) 79 (9.0)
>30 6 (4.3) 5 (4.5) 3 (3.8) 43 (4.9)
Unknown 51 (36.4) 25 (22.3) 20 (25.3) 273 (31.0)
CD4 count (cells/mm3) Median (IQR) 365 (230, 487) 274 (167, 451) 380 (253, 580) 392 (245, 580)
Nadir CD4 count (cells/m3) Median (IQR) 108 (53, 212) 134 (49, 232) 50 (16, 20) 127 (49, 245)
HIV RNA (log10 copies/ml) Median (IQR) 1.7 (1.7, 2.3) 1.7 (1.7, 3.8) 1.7 (1.7, 2.0) 1.7 (1.7, 2.4)
Prior NADC, n (%) 8 (5.7) 4 (3.6) 4 (5.1) 48 (5.5)
Prior ADC, n (%) 9 (6.4) 11 (9.9) 15 (19.0) 91 (10.3)
Year of diagnosis, n (%) 2004-2005 46 (32.9) 31 (27.7) 20 (25.3) 238 (27.0)
2006-2007 45 (32.1) 54 (48.2) 33 (41.7) 339 (38.5)
2008-2010 49 (35.0) 27 (24.1) 26 (32.9) 303 (34.4)
Smoking status, n (%) Current Smoker 71 (50.7) 45 (40.2) 40 (50.6) 386 (43.9)
Ex-smoker 55 (39.3) 30 (26.8) 22 (27.9) 253 (28.8)
Never smoked 3 (2.1) 21 (18.8) 9 (11.4) 136 (15.5)
Unknown 11 (7.9) 16 (14.3) 8 (10.1) 105 (11.9)
HCV positive, n (%) 11 (7.9) 5 (4.5) 8 (10.1) 75 (8.5)
HBV positive, n (%) 5 (3.6) 6 (5.4) 6 (7.6) 55 (6.3)
Any use of ARV, n (%) 130 (92.9) 99 (88.4) 78 (98.7) 813 (92.4)
Stage of disease, n (%) N 76 36 51 Not Collected
Localised 18 (23.7) 6 (16.7) 31 (60.8)
Disseminated 58 (76.3) 30 (83.3) 20 (39.2)
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participants). The numbers dying from their NADC for
the lung cancer, anal cancer and Hodgkin’s lymphoma
patients were 84 (94.4%), 17 (85.0%) and 16 (64.0%), re-
spectively, whereas the numbers dying from a non-
malignant cause were 1 (1.1%), 2 (10.0%) and 1 (4.0%),
respectively. One person (4.0%) with Hodgkin’s lymph-
oma died from an ADC. Information on the cause of
death was unknown for 4 (4.5%), 1 (5.0%) and 7 (28.0%)
of the three groups, respectively.Predictors of mortality
In univariate analyses, poorer survival after NADC diag-
nosis was associated with the type of NADC (with those
with lung cancer having a much higher mortality rate),
male gender, IDU mode of infection, non-white/unknown
ethnicity, smoking status, co-infection with HCV or HBV
and older age at diagnosis, whereas later year of diagnosis,
a higher nadir CD4 count and higher CD4 count at
NADC diagnosis were associated with improved survival.
No significant association was seen with the HIV RNA
02
4
6
8
In
ci
de
nc
e 
(/1
00
0
pe
rs
on
-y
ea
rs
)
Calendar year
a) 
0
2
4
6
8
In
ci
de
nc
e 
(/1
00
0
pe
rs
on
-y
ea
rs
)
Calendar year
b) 
0
2
4
6
8
In
ci
de
nc
e 
(/1
00
0
pe
rs
on
-y
ea
rs
)
Calendar year
c) 
0
2
4
6
8
In
ci
de
nc
e 
(/1
00
0
pe
rs
on
-y
ea
rs
)
Calendar year
d) 
Figure 1 Crude incidence rate (/1000 PY) of NADC, with 95% confidence intervals, stratified by calendar year. a) any NADC (880 events),
b) lung cancer (140 events), c) anal cancer (79 events), d) Hodgkin’s lymphoma (112).
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Figure 2 Cumulative mortality following diagnosis of NADC, stratified by type of NADC.
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http://www.biomedcentral.com/1471-2334/13/471level at NADC diagnosis, although the power to detect a
significant association was low as most patients were vir-
ally suppressed at the time. In adjusted analyses, most of
these factors remained associated with mortality (left-hand
side, Table 4); the exceptions to this were age, HCV status
and the nadir CD4 count, which were no longer associated
with mortality after controlling for the patient’s CD4 count
at diagnosis and other covariates. There was some evi-
dence that the effect of calendar year strengthened as the
time from diagnosis increased, consistent with a reduction
in the risk of both cancer-related and non-cancer-related
mortality in more recent years. Of interest, neither a previ-
ous NADC nor a previous ADC was strongly associated
with mortality in univariate analyses.
Analyses of risk factors for mortality after diagnosis of
specific NADC were limited due to the relatively small
number of patients experiencing these events. However, in
multivariable analyses, HCV co-infection and dissemi-
nated cancer at time of diagnosis were predictors of mor-
tality among patients with lung cancer (Table 4). Risk
factors for poorer survival after anal cancer were a previ-
ous NADC, HCV co-infection and disseminated cancer at
time of diagnosis. Finally, HBV positivity, lower haemoglo-
bin level at NADC diagnosis and lower CD4 cell count
were associated with mortality after Hodgkin’s lymphoma.
Of note, no association was seen in univariate analyses be-
tween the latest CD4 count and mortality from either lung
(relative hazard per 50 cells/mm3 higher: 0.99 [95% confi-
dence interval 0.95-1.03], p = 0.70) or anal (1.02 [0.93-
1.12], p = 0.70) cancer.
In sensitivity analyses with an endpoint of cancer-
specific mortality (right-hand side, Table 4), we found
similar associations to those seen for all-cause mortal-
ity for gender, smoking status, year of diagnosis, HBV
status, CD4 count at diagnosis and type of cancer.
However, the associations previously seen with IDU
mode of HIV acquisition and non-white/other/
unknown ethnicity were reduced and were non-
significant. When our analyses were restricted to indi-
viduals diagnosed with lung cancer, anal cancer or HL,
associations were again broadly similar to those seen
for all-cause mortality, although due to the reduced
power of these analyses, confidence intervals for any
effects were generally wider.Discussion
Using an international cohort with centrally validated
endpoints, we describe 880 NADC diagnosed from
2004–2010. The overall incidence of NADC in this co-
hort of HIV-positive persons was 4.98/1000 PY (498/
100,000 PY) with no evidence of an increasing or de-
creasing incidence over the study period. Survival after
NADC diagnosis was poor (median 5.5 years), with overa third of patients dying; survival varied substantially de-
pending on the type of NADC.
Published estimates of the incidence of NADC vary
widely. For example, whilst our reported incidence is
similar to that in many studies [5,7,20,23], it is substan-
tially lower than reported in one study [8] and higher
than that in three others [6,24,25]. Of note, incidence es-
timates from some other studies e.g. [2,3,9] should be
interpreted with caution due to the restriction of the
population to those with AIDS, a group potentially at
higher risk of cancer due to their advanced stage of
immunodeficiency [23]. A direct comparison of the
changes in NADC incidence over time in these studies is
also difficult, as many of the earlier studies compared
changes in NADC incidence in the pre-and post-cART
eras. Both the ageing and prolonged exposure to im-
mune suppression that have occurred in the post-cART
era may have resulted in an increased cancer incidence.
However, with this caveat, findings regarding a change
in NADC incidence have been inconsistent, with some
studies reporting an increase in incidence over time
[3,4,6,8,9] but others either not seeing an increase [24]
or reporting an increase for specific NADC only [2,5].
Of interest, whilst one large cohort of HIV-positive indi-
viduals reported an increase in the incidence of NADC
from 1983–2001, the increase did not continue over the
period 2002–2007 [6], consistent with our finding of no
increase over the period 2004–2010.
Our findings of a stable incidence over time for anal
cancers are consistent with some studies [7,10,11]. In
contrast, several other studies have reported an increase
in incidence [3-5,9,26], which may also be apparent in
the non-HIV population [27]. As noted earlier, the ma-
jority of these studies compared incidence rates to the
pre-cART era, which may explain the different conclu-
sions. Furthermore, not all studies have taken account of
the ageing of the underlying population, which may be
expected to lead to an increase in the overall cancer rate.
However, it is also possible that differential ascertain-
ment of anal cancers between studies that are registry-
based (which may, in some countries, include collection
of data on pre-cancers) and studies that require confirm-
ation by histology, may contribute to the inconsistent
findings. Finally, trends may also be affected by any
changes to local and national anal cancer screening pol-
icies: reports from the participating D:A:D cohorts sug-
gest that screening in HIV clinics has not generally been
performed frequently or homogeneously across partici-
pating countries. Hence, we do not believe that this is
likely to be a major source of bias.
Poorer survival after NADC diagnosis was associated
with male gender, IDU mode of infection, non-white eth-
nicity, smoking status, coinfection with hepatitis B virus
and earlier year of NADC diagnosis. Similar associations
Table 4 Results from multivariable Cox proportional hazards regression models to identify independent associations
between factors at the time of diagnosis of NADC and subsequent all-cause mortality and cancer-specific mortality for
any NADC, and lung cancer, anal cancer and Hodgkin’s lymphoma separately
All-cause mortality Cancer-specific mortality
RH [95% CI] p-value RH [95% CI] p-value
Any NADC
Gender Male 1.69 [1.21, 2.36] 0.002 1.59 [1.11, 2.26] 0.01
Female Ref. - Ref. -
Mode of infection Heterosexual Ref. - Ref. -
MSM 0.84 [0.63, 1.11] 0.22 0.84 [0.62, 1.13] 0.24
IDU 1.35 [0.98, 1.87] 0.07 1.23 [0.87, 1.74] 0.24
Other/unknown 0.78 [0.48, 1.26] 0.30 0.72 [0.42, 1.22] 0.22
Ethnic group White Ref. - Ref. -
Non-white/other/not collected 1.25 [0.99, 1.56] 0.06 1.18 [0.93, 1.49] 0.19
Smoking status Current smoker 1.33 [0.88, 1.99] 0.17 1.43 [0.92, 2.23] 0.11
Ex-smoker 1.79 [1.18, 2.70] 0.006 1.88 [1.20, 2.94] 0.006
Non-smoker Ref. - Ref. -
Unknown 1.60 [0.99, 2.59] 0.05 1.69 [1.01, 2.83] 0.05
HBV status Positive 1.42 [0.96, 2.12] 0.08 1.38 [0.90, 2.12] 0.14
Negative Ref. Ref.
Year of diagnosis /later year 0.93 [0.86, 0.99] 0.04 0.91 [0.84, 0.98] 0.01
CD4 count at diagnosis /50 cells/mm3 higher 0.95 [0.93, 0.98] 0.0001 0.96 [0.94, 0.98] 0.0007
Type of NADC Lung cancer 2.28 [1.75, 2.98] 0.0001 2.43 [1.84, 3.21] 0.0001
Anal cancer 0.58 [0.36, 0.92] 0.02 0.55 [0.33, 0.92] 0.02
Hodgkin’s lymphoma 0.49 [0.32, 0.75] 0.001 0.36 [0.21, 0.60] 0.001
Other Ref. - Ref. -
Lung cancer
HCV status Positive 1.88 [0.97, 3.66] 0.06 2.02 [1.04, 3.95] 0.04
Negative Ref. - Ref. -
Stage of disease Disseminated 5.22 [1.85, 14.76] 0.002 4.84 [1.71, 13.74] 0.003
Localised Ref. - Ref. -
Unknown 5.95 [2.12, 16.74] 0.0007 5.69 [2.02, 16.06] 0.001
Anal cancer
HCV status Positive 4.97 [1.55, 15.89] 0.007 4.16 [1.18, 14.67] 0.03
Negative Ref. - Ref. -
Previous NADC 12.00 [2.98, 48.32] 0.0005 10.17 [1.96, 52.73] 0.006
Stage of disease Disseminated 2.49 [0.73, 8.54] 0.15 2.29 [0.65, 8.10] 0.20
Localised Ref. - Ref. -
Unknown 3.24 [0.94, 11.18] 0.06 2.43 [0.66, 8.95] 0.18
Hodgkin’s lymphoma
HBV status Positive 4.15 [1.16, 14.90] 0.03 3.32 [0.68, 16.21] 0.14
Negative Ref. - Ref. -
CD4 count at diagnosis /50 cells/mm3 higher 0.86 [0.74, 1.01] 0.06 0.80 [0.64, 0.99] 0.04
Haemoglobin at diagnosis /g/L higher 0.72 [0.55, 0.94] 0.02 0.82 [0.59, 1.14] 0.24
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survival in recent years may reflect an increased use of
cancer treatment in HIV-positive patients, as well as the
availability of improved ART regimens leading to greater
CD4 count increases, and a reduction in cancer risk be-
haviour (e.g. increased smoking cessation). Of note, an in-
dividual’s CD4 count at NADC diagnosis remains a strong
predictor of subsequent mortality for all NADC combined
(as well as for Hodgkin’s lymphoma), emphasising the
need for continued use of cART, even in those with
NADC. It is interesting that HCV and HBV co-infection
were associated with a higher mortality following any can-
cer (HBV), lung cancer (HCV), anal cancer (HCV) and
Hodgkin’s lymphoma (HBV); whilst co-infection itself may
lead to higher mortality, viral co-infection may also be a
marker for other lifestyle factors that may by themselves
place the individual at a higher risk of mortality. Whilst
older age was significantly associated with survival follow-
ing NADC diagnosis in univariate analyses, it did not re-
main significantly associated with survival in adjusted
analyses; this may reflect the relatively restricted age of the
underlying cohort population, and of cohort participants
at the time of NADC diagnosis.
Although there has been some suggestion that the in-
cidence of NADC is higher in patients with AIDS [28],
we did not find strong associations between mortality
and either a previous NADC or a previous ADC, with
the exception of anal cancer. We observed several im-
portant findings with regard to mortality and risk factors
for some specific NADC. Unsurprisingly, lung cancers
had the highest mortality rate, with 94% of those who
died dying from the lung cancer itself. This is a similar
rate to that reported from a study of lung cancer in in-
jection drug users [29]. It is noteworthy that in our study
there was no association between the CD4 count at lung
cancer diagnosis and subsequent mortality, consistent
with no effect of HIV on survival after this diagnosis.
However, the CD4 count was associated with mortality
following a diagnosis of Hodgkin’s lymphoma and any
NADC overall. As most of the deaths that did occur
were cancer-related, these findings may highlight a pos-
sible role of immune suppression in the development,
and subsequent control, of cancers. Subsequent analyses
of this cohort will investigate associations with immune
suppression in more detail. However, it is important to
note that other explanations for an association between
survival and the CD4 count cannot be ruled out. For ex-
ample, the finding may reflect bias that may be introduced
if patients with lower CD4 counts were not offered, or
could not tolerate anti-cancer treatments (we have limited
data on use of chemo- and/or radio-therapy, or on surgical
treatments for cancer).
Our mortality rates among patients with Hodgkin’s
lymphoma are similar to those previously reported inthe setting of HIV perhaps reflecting our contemporary
HIV population where the majority are well treated on
cART and with access to appropriate cancer care. One
study reported the impact of cART [30] on mortality,
another the impact of chemotherapy on advanced dis-
ease [31]. Somewhat larger discrepancies have been
reported in relation to survival after an anal cancer diag-
nosis – these could be explained by the inclusion of pre-
cancers or in situ cancers in some of the registry-based
studies (which may be expected to show better survival
outcomes) and a hypothetically increased use of different
treatment modalities in recent years. Our mortality rate
at two years (30%) is similar to that reported from recent
prospective studies in the UK [32] and the US [19],
whereas our reported five-year mortality rate (35%) is
somewhat lower than that from a smaller retrospective
study exploring the impact of chemotherapy and surgery
in HIV-positive and HIV-negative individuals (61%) [33].
As this study was performed over an earlier time-period
to our own and included patients with non-metastatic
invasive anal cancer, the results may not be directly
comparable.
We repeated our analyses of predictors of all-cause
mortality for the outcome cancer-specific mortality. As
such a large proportion of the deaths were due to cancer,
we did not expect the results to differ greatly, and this
was generally the case. Interestingly, when considering
cancer-related mortality following all NADC combined,
the associations previously seen with IDU mode of HIV
acquisition and non-white/other/unknown ethnicity
were weakened. This presumably reflecting a stronger
association of these factors with other, non-cancer,
causes of death, although lack of power cannot be ruled
out as a possible explanation. When our analyses were
restricted to individuals diagnosed with lung cancer, anal
cancer or HL, associations were similar to those
reported for all-cause mortality. Of note, whilst these
analyses provide some interesting findings, they address
a somewhat different question. From a clinical perspec-
tive, it is impossible to know in advance whether the pa-
tient will die of his/her underlying cancer or of a
different cause, and hence our primary analyses maybe
of more relevance to the treating physician.
Our study has several limitations. Unfortunately, infor-
mation on dissemination or stage of disease at diagnosis,
important risk factors for survival, was unavailable for
most patients. Furthermore, we do not systematically
collect information on socioeconomic status or alcohol
consumption as part of the D:A:D Study, both of which
are likely to be associated with survival outcomes. We
do suffer from some missing and incomplete data, par-
ticularly regarding smoking and HBV/HCV coinfection
status. As our analysis has focused on the first NADC
during prospective D:A:D follow-up for each individual,
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NADC, particularly those that may more commonly
occur as secondary cancers. However, only 46 patients
with a NADC in the present analysis developed a subse-
quent cancer, suggesting that the impact of any under-
estimation will be small. Finally, whilst we recognize that
individual NADC are very different, in terms of their
pathogenesis, natural history and therapeutic possibil-
ities, the low incidence of most specific types of NADC
meant that we were unable to consider these separately
(other than the three most commonly occurring NADC).
Even for the three most commonly occurring NADC,
our multivariable models to identify predictors of sur-
vival were restricted by low power. Thus, our analyses
were only able to identify the strongest predictors of sur-
vival and we cannot rule out the possibility that other
factors may also be associated with survival outcomes.
Further follow-up of this study may permit more de-
tailed analyses of specific NADC in the future.Conclusions
In conclusion, the incidence of NADC from 2004–10
has been stable in this large observational cohort with
an overall incidence of NADC of 4.98/1000 PY. The
prognosis after diagnosis of NADC, in particular lung
cancer and disseminated cancer, is poor but has im-
proved somewhat over time. A higher CD4 count at
diagnosis was associated with improved survival for
some cancers, and when considering NADC jointly.
Earlier diagnosis of both HIV and NADC, and research
into better management of NADC is warranted.Appendix
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